Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof

A method for delivering a therapeutically effective drug or pharmaceutical agent to a subject, comprising:

• a) administering a hyaluronidase glycoprotein to a tissue in the subject in an amount sufficient to degrade glycosaminoglycans, wherein:
• the hyaluronidase glycoprotein consists of the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482, or 36-483 of SEQ ID NO:
• 1, or contains amino acid substitutions in the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1, whereby the amino-acid substituted hyaluronidase glycoprotein consists of a sequence of amino acids that has at least 95% amino acid sequence identity with the sequence of amino acids set forth as amino acids 36-477, 36-478, 36-479, 36-480, 36-481, 36-482 or 36-483 of SEQ ID NO:1;
• the glycoprotein is neutral active;
• and
• the glycoprotein contains at least one sugar moiety that is covalently attached to an asparagine (N) residue of the polypeptide;
• and
• b) administering a therapeutically effective amount of the drug or pharmaceutical agent to the subject.